676495

VEGF Inhibitor, V1

The VEGF Inhibitor, V1 controls the biological activity of VEGF. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• Sinônimo(s): VEGF Inhibitor, V1, ATWLPPR
• Fórmula empírica (Notação de Hill): C₄₀H₆₁N₁₁O₉
• Peso molecular: 839.98
• Código UNSPSC: 12352200
• NACRES: NA.77

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥95% (HPLC)
• forma: lyophilized solid
• fabricante/nome comercial: Calbiochem^®
• condição de armazenamento: OK to freeze; desiccated (hygroscopic)
• cor: white
• solubilidade: DMSO: 5 mg/mL
• Condições de expedição: ambient
• temperatura de armazenamento: 2-8°C

Descrição

Descrição geral

An NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF₁₆₅ binding to recombinant NRP-1 in cell-free binding assays (IC₅₀ = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF₁₆₅ binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC₅₀ = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.

An NRP-1-binding heptapeptide whose target was initially mistaken as VEGFR2/KDR/Flk-1 due to its binding activity to a CHO-KDR culture that was later shown to express primarily NRP-1 and little KDR. V1/A7R specifically competes against VEGF₁₆₅ binding to recombinant NRP-1 in cell-free binding assays (IC₅₀ = 60 µM), while exhibiting no activity against the interaction between NRP-1 and heparin or VEGF₁₆₅ binding to KDR, VEGFR1/Flt-1, and heparin. V1/A7R is demonstrated to inhibit VEGF-dependent angiogenesis activity in HMVEC (IC₅₀ = 0.3 µM) and HUVEC cultures in vitro, as well as in a rabbit corneal neovascularization model and in mice bearing MDA-MB-231-derived tumor in vivo.

Ações bioquímicas/fisiológicas

Cell permeable: no

Primary Target
Specifically competes against VEGF165 binding to recombinant NRP-1

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 60 µM for specifically competes against VEGF165 binding to recombinant NRP-1 in cell-free binding assays

Embalagem

Packaged under inert gas

Advertência

Toxicity: Standard Handling (A)

Sequência

H-Ala-Thr-Trp-Leu-Pro-Pro-Arg-OH

Outras notas

Starzec, A., et al. 2006. Life Sci.79, 2370.
Binetruy-Tournaire, R., et al. 2000. EMBO J.19, 1525.

Informações legais

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informações de segurança

• Código de classe de armazenamento: 11 - Combustible Solids
• Classe de risco de água (WGK): WGK 1
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable